Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top line, with revenue of $61.7M vs. $68.0M expected. While Payor revenue grew 27.1% YoY, it was offset by a 26.8% decline in DTE and a 25.4% drop in Consumer revenue. Despite the revenue miss, GAAP EPS of -$0.01 beat the -$0.035 mean estimate, aided by rigorous cost controls in R&D and Clinical Operations. The company remains in a pending merger with Universal Health Services (UHS) at $5.25 per share, expected to close in Q3 2026.